solanezumab: Clinical Trials

8 trials of solanezumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 3 terminated, 1 active not recruiting. 8 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Completed 4, Terminated 3, Active not recruiting 1
Phase 22Active not recruiting 1, Completed 1

Follow solanezumab: new trials by email Literature Review of solanezumab trials Research Report on solanezumab

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Solanezumab, Placebo - Alzheimer's Disease
Phase 3TerminatedEli Lilly and Company262016-06-012019-10-10
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Placebo, Solanezumab - Cognition Disorders
Phase 3CompletedEli Lilly and Company11692014-02-282026-08-21
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Solanezumab, Placebo - Alzheimer's Disease
Phase 3TerminatedEli Lilly and Company21292013-07-012019-10-09
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab) - Alzheimers Disease, Dementia
Phase 2 / Phase 3CompletedWashington University School of Medicine1942012-12-012022-09-22
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab) - Alzheimers Disease, Dementia
Phase 2 / Phase 3Active not recruitingWashington University School of Medicine4902012-12-012026-11-19
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Solanezumab, Placebo - Alzheimer's Disease
Phase 3TerminatedEli Lilly and Company14572010-12-012019-10-08
Effect of LY2062430 on the Progression of Alzheimer's Disease
LY2062430, Placebo - Alzheimer's Disease
Phase 3CompletedEli Lilly and Company10002009-05-012012-09-25
Effect of LY2062430 on the Progression of Alzheimer's Disease
LY2062430, Placebo - Alzheimer's Disease
Phase 3CompletedEli Lilly and Company10402009-05-012012-12-13

Conditions studied

Alzheimer Disease (7)  ·  Dementia (2)  ·  Cognition Disorders (1)

Sponsors

Eli Lilly and Company (6)  ·  Washington University School of Medicine (2)

Countries

United States (8)  ·  Canada (7)  ·  Japan (7)  ·  Australia (6)  ·  France (6)  ·  Spain (6)  ·  United Kingdom (6)  ·  Germany (5)  ·  Italy (5)  ·  Poland (4)  ·  Sweden (4)  ·  Argentina (3)  ·  Brazil (3)  ·  Puerto Rico (3)  ·  Taiwan (3)

Top investigators

Randall J Bateman, MD (2)

Results publications

PMID 36946603, PMID 40603145, PMID 24450890, PMID 25125457, PMID 26120369, PMID 26402769, PMID 29615123, PMID 29365294, PMID 35197359, PMID 35543002, PMID 36110925, PMID 37017737, PMID 37458272, PMID 38230716, PMID 38683602, PMID 39044494, PMID 39044495, PMID 39044496, PMID 39044497, PMID 39974075, PMID 40120616, PMID 40440591, PMID 40476544, PMID 40985290, PMID 40990131, PMID 41001450, PMID 41085172, PMID 41537338, PMID 41926844, PMID 41963989, PMID 42295275, PMID 42657501

NIH funding

R01AG046179 (2), U01AG042791 (2), 2016 (1), R01AG053267 (1), R56AG053267 (1), U01AG059798 (1)